New stock awards and tax share withholdings for BioLife (BLFS) CEO

Rhea-AI Filing Summary

BioLife Solutions President and CEO Roderick De Greef reported several equity awards and related tax withholdings. On February 24, 2026, he acquired three blocks of restricted common stock totaling 118,730, 170,291 and 219,024 shares at a stated price of $0.00 per share.

The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan, including 2026 compensation that vests 25% on the first anniversary and then in 12 equal quarterly installments. Other restricted stock vested based on total shareholder return from January 1, 2024 to December 31, 2025 versus peers and on specific performance metrics, leading to vesting at approximately 156% and 200% of target.

To satisfy tax withholding obligations on the market‑ and performance‑based vesting, 67,010 and 86,186 shares were disposed of at $22.65 per share through share withholding rather than open‑market sales. After these transactions, De Greef directly held 744,847 shares of BioLife Solutions common stock.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider DE GREEF RODERICK

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	118,730	$0.00	--
Grant/Award	Common Stock	170,291	$0.00	--
Tax Withholding	Common Stock	67,010	$22.65	$1.52M
Grant/Award	Common Stock	219,024	$0.00	--
Tax Withholding	Common Stock	86,186	$22.65	$1.95M

Holdings After Transaction: Common Stock — 508,728 shares (Direct)

Footnotes (1)

1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the number of shares granted based on specific performance metrics of the registrant during the period beginning on January 1, 2024 through December 31, 2025. Represents shares withheld to cover tax withholding obligations in connection with the vesting of the performance-based restricted stock award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DE GREEF RODERICK

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		118,730	A	(1)	508,728	D
Common Stock	02/24/2026		A		170,291	A	(2)	679,019	D
Common Stock	02/24/2026		F		67,010	D	$22.65(3)	612,009	D
Common Stock	02/24/2026		A		219,024	A	(4)	831,033	D
Common Stock	02/24/2026		F		86,186	D	$22.65(5)	744,847	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation.

2. The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

3. Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.

4. The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the number of shares granted based on specific performance metrics of the registrant during the period beginning on January 1, 2024 through December 31, 2025.

5. Represents shares withheld to cover tax withholding obligations in connection with the vesting of the performance-based restricted stock award.

Remarks:

	/s/ Roderick de Greef	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BioLife Solutions (BLFS) CEO report in this Form 4 filing?

The filing shows CEO Roderick De Greef received multiple restricted stock grants and vesting awards, plus related tax share withholdings. All transactions involve BioLife Solutions common stock granted under the 2023 Omnibus Performance Incentive Plan as part of his compensation structure.

How many BioLife Solutions (BLFS) shares were granted to the CEO?

De Greef reported three restricted stock acquisitions of 118,730, 170,291 and 219,024 common shares at a stated price of zero. These awards were issued under the 2023 Omnibus Performance Incentive Plan as part of 2026 compensation and previously granted performance and market-based stock programs.

Were any BioLife Solutions (BLFS) shares sold on the open market in this Form 4?

No open‑market sales are reported. Instead, 67,010 and 86,186 shares of common stock were withheld at $22.65 per share to cover tax obligations arising from vesting of market‑based and performance‑based restricted stock awards granted under the company’s 2023 Omnibus Performance Incentive Plan.

What performance period affected the BioLife Solutions (BLFS) CEO’s vested stock awards?

Certain restricted stock vested based on performance during the period from January 1, 2024 through December 31, 2025. Vesting depended on total shareholder return versus a peer group and specific company performance metrics, resulting in vesting at approximately 156% and 200% of the original granted share targets.

How were the BioLife Solutions (BLFS) CEO’s tax obligations handled for these equity awards?

Tax liabilities tied to vesting were satisfied by share withholding rather than cash payments. The company withheld 67,010 shares from a market-based award and 86,186 shares from a performance-based award, each valued at $22.65 per share, to cover required tax withholdings.

What is the BioLife Solutions (BLFS) CEO’s direct share ownership after these transactions?

Following the reported grants, vesting events, and tax share withholdings, Roderick De Greef directly owned 744,847 shares of BioLife Solutions common stock. This figure reflects his post‑transaction balance as disclosed in the final line of the non‑derivative transaction table in the filing.